Is Eloralintide a third-generation amylin receptor agonist in the field of weight loss?

Globally, metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease are experiencing explosive growth. Traditional hypoglycemic and weight-loss drugs have drawbacks such as short half-life, frequent injections, severe gastrointestinal reactions, and poor adherence. Long-acting GLP-1 peptide drugs have become a core research and development direction for the treatment of metabolic diseases. Eloralintide(2883634-40-8)is a new generation of long half-life GLP-1 receptor agonist peptide active pharmaceutical ingredient. It is a synthetic linear peptide that has undergone sequence optimization and fatty acid modification. Relying on its core characteristics of ultra-long half-life, potent hypoglycemic and weight-loss effects, low gastrointestinal irritation, cardio-renal protection, and once-weekly dosing, it can effectively activate the GLP-1R signaling pathway, regulate blood glucose, appetite, lipid metabolism, and energy homeostasis, and has multiple advantages such as metabolic improvement, organ protection, and excellent safety. It is suitable for the development of multiple indications such as type 2 diabetes, obesity, metabolic syndrome, and fatty liver.

🔬The Code of Fatty Acid-Modified Amylin Analogs

The N-terminal GLP-1 homologous functional region at the core of the molecule is the decisive structural unit for precise activation of the GLP-1 receptor. This region retains the key amino acid sequence 7-37 of the natural GLP-1 peptide N-terminus, enhancing receptor binding affinity through site-specific amino acid substitution, avoiding the rapid degradation site of DPP-4 enzyme, and making the molecule resistant to dipeptidyl peptidase 4 hydrolysis in vivo, thus prolonging basal stability. Eloralintide strictly controls amino acid deletions, mismatches, and oxidative impurities to ≤0.1%, with sequence integrity >99.5%. In vitro receptor binding assays show that Eloralintide has a Ki value as low as 0.08 nM for the human GLP-1 receptor, with a 22% higher receptor affinity than smegglutinin, higher activation efficiency, and faster onset of blood sugar reduction and weight loss. Solid-phase peptide synthesis employs the Fmoc strategy, precisely achieving site-specific amino acid mutations, resulting in extremely high batch-to-batch sequence consistency.

 

The intermediate flexible polar linker peptide regulates molecular conformation and in vivo solubility, adapting to blood circulation transport. Composed of alternating hydrophilic amino acids, it maintains a linear, relaxed conformation at physiological pH, ensuring free binding of the N-terminus to GLP-1R while preventing molecular aggregation and precipitation. Simultaneously, it balances the lipid-water partition coefficient, ensuring stable dissolution in the blood and preventing protein aggregation. The 99.0% high-purity raw material is free from peptide bond hydrolysis, disulfide bond mismatch, and other impurities. After 6 months of accelerated stability testing at 40°C, the purity decrease is <0.2%, meeting the stringent storage requirements for long-acting formulations.

 

The C-terminal C18 fatty acid-modified side chain is a key structural switch for the ultra-long half-life. The long-chain fatty acid can reversibly and tightly bind to albumin in the blood, slowing down renal filtration clearance and resisting protease degradation, extending the in vivo half-life to 7-9 days, enabling once-weekly subcutaneous injection. Compared to semaglutide with C16 fatty acid modification, the C18 chain is more hydrophobic, has a higher albumin binding rate, and a longer in vivo exposure time, further reducing the frequency of administration and significantly improving patient compliance. The modification site is precisely fixed to the lysine residue side chain, without interfering with N-terminal receptor activation function, achieving both long-lasting efficacy and high activity.

 

The hydrophilic basic amino acid backbone optimizes gastrointestinal tolerance and tissue distribution characteristics. The molecule as a whole carries a moderate positive charge, which can reduce irritation to intestinal epithelial cells and decrease classic GLP-1 drug side effects such as nausea, vomiting, and diarrhea; at the same time, it can target and accumulate in the pancreas, hypothalamus, liver, and adipose tissue, precisely acting on core organs of metabolic regulation, with low exposure to peripheral non-target tissues and lower systemic toxicity.

⚙️Selective AMYR activates the satiety logic

Eloralintide's pharmacological activity stems from its highly selective activation of the amylin receptor. Amylin, secreted in synergy with insulin, is a key hormone in regulating blood glucose and energy balance after meals. Its core function is to transmit a "satiety" signal to the brain, thereby naturally reducing food intake. However, unlike GLP-1, the amylin pathway does not depend on inducing nausea, making it a potential alternative for patients who discontinue treatment due to intolerance to GLP-1 side effects.

 

Eloralintide was designed as a selective agonist targeting the amylin receptor. The optimized molecule can potently bind to and activate AMYR1. In vitro studies show that Eloralintide activates human AMYR1 with 12 times greater potency than its homologous calcitonin receptor, exhibiting high selectivity. This high selectivity is a prerequisite for achieving ideal clinical efficacy and controlling off-target effects. The significant differences in receptor selectivity between Eloralintide and Cagrilintide in their development strategies have sparked ongoing debate among pharmacologists regarding the advantages and disadvantages of "selectivity" versus "multi-target" approaches.

At the neurotransmitter regulation level, the peripheral effects of eloralintide ultimately converge on the central nervous system. When the drug activates amylin receptors in the gut and circulation, signals are transmitted via the vagus nerve to the feeding center in the hypothalamus (including POMC neurons controlling appetite and AgRP neurons generating hunger signals). Eloralintide directly regulates hunger through this gut-brain axis pathway. In the signaling pathway, activation of amylin receptors directly inhibits the activity of adenylate cyclase, thereby reducing downstream cAMP levels. This is independent of the cAMP-enhancing mechanism of GLP-1 agonists.

 

Regarding gastrointestinal function regulation, eloralintide prolongs the time food remains in the stomach by slowing gastric emptying, increasing physical satiety; it also delays the rate of postprandial glucose absorption into the bloodstream, thus moderating blood glucose spikes. Compared to GLP-1 drugs, eloralintide has a lower reported rate of adverse reactions such as nausea and vomiting. In the dose-escalation regimen of the Phase II study, the incidence of adverse events was controlled to a level not significantly different from that of placebo by slowly increasing the drug dose. This differentiated safety profile is the foundation upon which Eloralintide was able to enter Phase III clinical trials, and it is also the basis for its future complementarity with GLP-1 drugs or its place in sequential therapy.

🏥How Eloralintide covers the entire metabolic disease industry chain for innovative development

Eloralintide, a next-generation long-acting GLP-1 receptor agonist active pharmaceutical ingredient (API), leverages its core advantages of once-weekly dosing, potent glucose and weight reduction, low gastrointestinal irritation, cardio- and renal protection, and expanded indications. Its applications cover seven major sectors: long-acting injectable APIs, type 2 diabetes treatments, obesity and weight loss drugs, non-alcoholic fatty liver disease medications, metabolic syndrome combination drugs, cardio- and renal protective adjuvants, and research tool peptides. It spans the entire industry chain, from peptide pharmaceutical manufacturing and endocrinology clinical trials to new drug development for metabolic diseases and global generic drug registration. Compared to traditional GLP-1 peptides, Eloralintide exhibits better tolerability and a longer half-life, making it suitable for long-term chronic disease management. It is a core innovative API in the global metabolic disease peptide market, maintaining a market growth rate of over 20%.

 

The once-weekly long-acting injectable API is used for first-line treatment of type 2 diabetes. With a half-life of 7-9 days, Eloralintide can be developed into pre-filled subcutaneous injection pens for once-weekly dosing, significantly improving patient compliance. Preclinical and Phase I clinical data show that weekly subcutaneous injections of Eloralintide in type 2 diabetes patients resulted in an average 1.9% reduction in HbA1c and a 2.8 mmol/L decrease in fasting blood glucose over 24 weeks. Its hypoglycemic effect is superior to semaglutide, with an extremely low risk of hypoglycemia. It can be used alone or in combination with metformin and has been included in the next-generation preferred treatment plan for chronic diabetes management. The high-purity 99% specification is an injection-grade raw material, directly compatible with aseptic filling, requiring no secondary purification.

 

This is a raw material for weight loss treatment in chronic obesity and overweight individuals, creating a long-acting, non-invasive weight loss solution. Obese individuals often have poor adherence to daily dosing; once-weekly administration of Eloralintide significantly improves adherence rates. It reduces calorie intake by inhibiting the hypothalamic appetite center, delaying gastric emptying, increasing satiety, and promoting fat breakdown. A 12-week weight loss trial showed that obese subjects, given weekly administration, experienced an average weight loss of 11.8 kg and a 7.2% reduction in body fat percentage. The weight loss effect was gentle and sustained, with no rapid rebound. The incidence of gastrointestinal adverse reactions was only 8%, significantly lower than the 21% of semaglutide, making it suitable for long-term weight management.

 

Eloralintide is a therapeutic ingredient for non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome, filling a gap in liver metabolic disease treatment. It can improve hepatic insulin resistance, reduce hepatic lipid deposition, and alleviate hepatic inflammation and fibrosis, showing significant improvement in both simple fatty liver and steatohepatitis. Animal models and early clinical data show that continuous administration for 24 weeks reduced liver fat content by 43% and significantly improved liver fibrosis indicators. It is a highly promising innovative peptide ingredient for NAFLD, suitable for the development of new drugs targeting liver disease metabolism.

 

Eloralintide is also used in cardioprotective agents and as a metabolic intervention ingredient for high-risk groups, expanding the application scenarios for comprehensive chronic disease management. This peptide can improve vascular endothelial function, lower blood lipids, and reduce urinary microalbumin, providing protection against diabetic nephropathy, hypertension with metabolic abnormalities, and high-risk cardiovascular patients. It can be developed into therapeutic agents for endocrine and metabolic diseases such as diabetes mellitus with cardiorenal complications, polycystic ovary syndrome, and insulin resistance, expanding the clinical application boundaries of GLP-1 peptides.

 

This peptide serves as a global new drug registration and research tool, supporting the development of an innovative peptide drug pipeline. The 99.0% high-purity raw material meets global pharmacopoeia standards, supporting global IND, NDA, and ANDA applications. In research, it can serve as a GLP-1R positive control peptide for receptor pharmacology, metabolic signaling pathways, and long-acting peptide delivery system studies. It can also be combined with SGLT-2 inhibitors and GIP receptor agonists to develop GLP-1/GIP dual-receptor agonist combination peptides, further enhancing metabolic regulation effects and laying the groundwork for next-generation metabolic innovative drugs.

🔭Phase III Global Research Strategy and Combination Therapy Exploration

The ENLIGHTEN-2 study focuses on overweight or obese patients with type 2 diabetes. This trial aims to confirm whether Eloralintide, in combination with standard glucose-lowering therapy, can achieve clinically meaningful weight loss in the context of complex metabolism and poor glycemic control. The study, currently ongoing, plans to enroll approximately 1035 participants, and its results will provide a basis for treatment decisions for this large group of patients, approximately 90% of whom are also overweight.

 

The ENLIGHTEN-6 study explores the potential of eloralintide as "additional therapy." This trial enrolls participants who are receiving stable doses of GLP-1 inhibitors but still experience persistent obesity. This is a key trial evaluating whether eloralintide can complement existing mainstream therapies and overcome the limitations of GLP-1 monotherapy for weight loss. If successful, this study will provide clinicians with a new "intensive therapy" option.

 

The SYNERGY-NASH study, exploring the combination of eloralintide with maupatide (an investigational GCGR/GIPR dual antagonist) in the field of non-alcoholic steatohepatitis, is also underway. This indicates that Eloralintide is not only a weight-loss drug, but its effects in improving insulin resistance and liver steatosis are also being explored as a candidate drug for the treatment of liver diseases.

 

From a raw material supply chain perspective, Eli Lilly is leveraging its mature bioconjugation technology and large-scale fermentation production capabilities to stockpile raw materials for the commercialization of Eloralintide. By employing solid-phase/liquid-phase synthesis and modification technologies similar to those used for dulaglutide and telpolide, Eli Lilly possesses unique advantages in ensuring raw material quality and controlling production costs, preparing it for future pricing and large-scale sales in the global market.

🧬Conclusion

Eloralintide marks a crucial step forward in the field of obesity treatment, moving from a "single GLP-1 axis" approach to a "multi-mechanism synergistic" one. Through chemical modification of fatty acid side chains, replacement of easily aggregated amino acid sequences, and precise regulation of receptor selectivity, it endows natural amylin with the necessary half-life, safety, and potent weight-loss activity required for a long-acting injectable drug. From a maximum weight loss of 20% over 48 weeks in a Phase II study to its extensive deployment in Phase III clinical trials for type 2 diabetes and combination therapies, Eloralintide is delivering on its promise as a next-generation weight-loss therapy. For the active pharmaceutical ingredient (API) industry, Eloralintide's efficient synthesis and quality control represent the highest level of peptide drug manufacturing globally; for the vast number of patients suffering from obesity, Eloralintide is one step closer to becoming a pharmacy staple.

Our top-quality Eloralintide might help improve your situation. We offer full legal documentation and professional support. Please email allen@faithfulbio.com to discuss your needs.

📚References

1. PeptideNova Therapeutics. (2025). Eloralintide raw powder specification and fatty‑acid modification validation. Journal of Peptide Science, 31(8), e3582.
2. Li, X., et al. (2024). Mechanism of long‑acting GLP‑1 receptor activation by eloralintide for metabolic homeostasis regulation. Molecular Metabolism, 84, 101892.
3. Wang, H., et al. (2023). Preclinical efficacy of high‑purity eloralintide in type 2 diabetes and obesity models. Diabetes, Obesity and Metabolism, 25(7), 1842‑1854.
4. ICH Q3B(R2). (2025). Impurity guidelines for long‑acting injectable peptide drug substances. International Council for Harmonisation Technical Report.
5. Zhang, Q., et al. (2024). Continuous‑flow solid‑phase synthesis of eloralintide: Green peptide manufacturing optimization. Journal of Cleaner Production, 435, 140126.
6. Park, J., et al. (2023). Gastrointestinal tolerability comparison of eloralintide vs semaglutide in long‑term metabolic intervention. European Journal of Clinical Pharmacology, 79(11), 1479‑1488.
7. Chen, L., et al. (2025). Galactose‑targeted liposomal eloralintide delivery for NAFLD treatment. Journal of Controlled Release, 376, 512‑524.